

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

APPOINTMENT AND RESIGNATION OF EXECUTIVE DIRECTOR

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that with effect from 6 December 2024:

- (1) Dr. Jiang Hao (“**Dr. Jiang**”) has resigned as an Executive Director of the Company due to work reassignment. He will continue to serve as General Manager of the Group’s Business Development Department; and
- (2) Mr. Chen Weiping (“**Mr. Chen**”) has been appointed as an Executive Director of the Company.

Dr. Jiang has confirmed that he has no disagreement with the Board and is not aware of any matters relating to his resignation that need to be brought to the attention of shareholders of the Company.

Set out below are the biographical details of Mr. Chen:

Mr. Chen Weiping

Mr. Chen, aged 45, who joined the Group in July 2004, is currently an Executive President and the General Manager of the Operation Management Centre of the Group, primarily responsible for the production operation of the Group. Mr. Chen has previously served as Workshop Director, Assistant to General Manager, Deputy General Manager and General Manager of CSPC Weisheng Pharmaceutical (Shijiazhuang) Co., Ltd., a wholly-owned subsidiary of the Company, and President of the Group’s No. 2 Manufacturing Centre. Mr. Chen holds a Bachelor’s degree in Engineering (Environmental Engineering) from Hebei University of Science and Technology, and is also a senior engineer and a national registered safety engineer.

The Company has entered into a service contract with Mr. Chen for a term of three years and he is subject to retirement and re-election at the annual general meeting of the Company in accordance with the articles of association of the Company. Mr. Chen is entitled to receive a monthly salary of RMB60,000 and an annual director's fee of HK\$63,000 under his service contract. In addition, he is also eligible to receive performance related discretionary bonus to be determined by the Board. His emoluments were determined by the Board based on the recommendations of the remuneration committee and with reference to his experience, responsibilities with the Company, current market practices and the remuneration policy of the Company.

As at the date of this announcement, Mr. Chen has personal interests in 20,000 shares of the Company and unvested share awards of 500,000 shares of the Company granted by Key Honesty Limited, a shareholder of the Company which is wholly owned by Mr. Cai Dongchen, a substantial shareholder of the Company, within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Mr. Chen does not have any relationship with any director, senior management, substantial shareholder or controlling shareholder, and has not held any other directorships in any other public listed companies in the past three years.

Save as disclosed above, Mr. Chen confirmed that there is no other information that needs to be disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, and there are no other matters concerning his appointment that need to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to express its sincere gratitude to Dr. Jiang for his contributions during the tenure of his office, and would also like to extend a warm welcome to Mr. Chen on his appointment.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 6 December 2024

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.